[1]张阳慧.吡拉西坦、依达拉奉及长春西汀联合治疗出血性脑梗死的效果及安全性研究[J].医学信息,2026,39(05):140-143.[doi:10.3969/j.issn.1006-1959.2026.05.025]
　ZHANG Yanghui.Study on the Efficacy and Safety of Piracetam, Edaravone and Vinpocetinein the Treatment of Hemorrhagic Cerebral Infarction[J].Journal of Medical Information,2026,39(05):140-143.[doi:10.3969/j.issn.1006-1959.2026.05.025]
点击复制

吡拉西坦、依达拉奉及长春西汀联合治疗出血性脑梗死的效果及安全性研究()

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
39卷
期数:
2026年05期
页码:
140-143
栏目:
临床证据信息
出版日期:
2026-03-01

文章信息/Info

Title:
Study on the Efficacy and Safety of Piracetam, Edaravone and Vinpocetinein the Treatment of Hemorrhagic Cerebral Infarction
文章编号:
1006-1959（2026）05-0140-04
作者:
张阳慧
天津北大医疗海洋石油医院神经内科，天津 300452
Author(s):
ZHANG Yanghui
Department of Neurology, Tianjin PKUCare CNOOC Hospital, Tianjin 300452, China
关键词:
吡拉西坦; 依达拉奉; 长春西汀; 出血性脑梗死
Keywords:
Piracetam;  Edaravone;  Vinpocetine;  Hemorrhagic cerebral infarction
分类号:
R743.33
DOI:
10.3969/j.issn.1006-1959.2026.05.025
文献标志码:
A
摘要:
目的 分析吡拉西坦、依达拉奉及长春西汀联合治疗出血性脑梗死的效果及安全性。方法 将2021年6月-2024年5月天津北大医疗海洋石油医院收治的80例出血性脑梗死患者按照随机数字表法分为研究组和对照组，每组40例。对照组给予吡拉西坦、依达拉奉治疗，研究组在此基础上增加长春西汀治疗。比较两组临床疗效、美国国立卫生院卒中量表（NIHSS）评分、脑血肿体积、不良反应发生率（嗜睡、食欲减退、腹痛腹泻、恶心呕吐）。结果 研究组治疗总有效率高于对照组，治疗后NIHSS评分低于对照组，脑血肿体积小于对照组（P＜0.05）。两组不良反应发生率比较，差异无统计学意义（P＞0.05）。结论 吡拉西坦、依达拉奉及长春西汀联合治疗出血性脑梗死的效果确切，对于患者的神经功能改善、脑血肿体积减少有积极作用，且安全性较高。
Abstract:
Objective To analyze the efficacy and safety of piracetam, edaravone and vinpocetine in the treatment of hemorrhagic cerebral infarction. Methods From June 2021 to May 2024, 80 patients with hemorrhagic cerebral infarction admitted to Tianjin PKUCare CNOOC Hospital were selected as the research objects. Using the random number table method, they were assigned to study group and control group, with 40 patients in each group. The control group received combined medication with piracetam and edaravone, while the study group was given additional vinpocetine. A comparison was made between the two groups in terms of clinical efficacy, National Institutes of Health Stroke Scale (NIHSS) scores, intracerebral hematoma volume, and the incidence of adverse reactions (drowsiness, decreased appetite, abdominal pain and diarrhea, nausea and vomiting). Results The study group demonstrated a significantly higher total effective rate of treatment, along with lower NIHSS scores and smaller intracerebral hematoma volumes after treatment compared to the control group (P<0.05). No significant difference was noted between the groups in terms of adverse reaction rates (P>0.05). Conclusion The combination of piracetam, edaravone, and vinpocetine significantly improves neurological function and reduces cerebral hematoma volume in patients with hemorrhagic cerebral infarction, with a favorable safety profile.

参考文献/References:

[1]邵宽河,邱朝霞,陈思静.依达拉奉联合rt-PA治疗急性脑梗死患者的临床效果及对出血性转化的影响因素分析[J].临床误诊误治,2020,33(6):42-46.[2]许春梅,樊蓉,张丽.依达拉奉在急性脑梗死患者rt-PA静脉溶栓后出血性转化中的作用[J].中国医药导报,2020,17(17):79-83.[3]孙凡,刘恒,徐倩倩,等.依达拉奉对急性脑梗死的疗效及其对出血性转化的影响[J].中国现代医学杂志,2019,29(3):78-82.[4]李军涛,郭林霞,李国山,等.依达拉奉对急性脑梗死患者rt-PA静脉溶栓后出血性转化的影响[J].卒中与神经疾病,2019,26(1):47-50,59.[5]欧阳葵,张勇,陈尼卡,等.银杏酮酯片联合依达拉奉治疗出血性脑梗死疗效及对神经功能的影响[J].中华中医药学刊,2021,39(4):160-162.[6]张建强,焦永平.脉血康胶囊与依达拉奉联合治疗对出血性脑梗死患者血清MMP-9、S100β蛋白水平和神经功能的影响[J].陕西中医,2018,39(11):1521-1523.[7]韩薇,徐宇浩,于明.依达拉奉右莰醇注射液治疗急性大动脉粥样硬化型脑梗死患者的临床研究[J].中国临床药理学杂志,2023,39(3):316-319.[8]胡樑臣,李可静,于学会,等.依达拉奉右莰醇联合丁苯酞对急性脑梗死患者静脉溶栓后神经功能缺损程度及神经元保护作用[J].微循环学杂志,2023,33(1):33-37.[9]孙凡,刘恒,徐倩倩,等.依达拉奉注射液对急性脑梗死溶栓患者MMP-9水平、出血性转化以及神经功能缺损评分的影响[J].心脑血管病防治,2019,19(3):252-254.[10]钱时德,赵全,焦冬生,等.依达拉奉联合重组组织型纤溶酶原激活剂静脉溶栓治疗急性脑梗死疗效观察[J].新乡医学院学报,2020,37(11):1040-1043,1048.[11]雷俊娜,程南方,李旷怡,等.高渗氯化钠注射液联合吡拉西坦治疗急性脑梗死并脑出血临床评价[J].中国药业,2021,30(2):86-88.[12]张静静,吕荣祥,刘郁,等.吡拉西坦注射液联合前列地尔对老年出血性脑梗死急性期患者神经功能、血管内皮功能、炎症因子和血液流变学的影响[J].中国老年学杂志,2018,38(10):2337-2339.[13]高守君,李婧,吴艺,等.依达拉奉联合长春西汀注射液治疗急性脑出血的临床研究及对神经功能的影响[J].河北医学,2019,25(1):123-127.[14]李瑞峰,许斌,侯兵,等.脑得生片联合长春西汀治疗脑出血恢复期的临床研究[J].现代药物与临床,2021,36(5):1000-1003.[15]潘才钰,盛和静,薛思源.化瘀涤痰利脑汤联合长春西汀片治疗老年高血压脑出血恢复期的临床研究[J].中华中医药学刊,2019,37(3):746-750.[16]董智强,陈旭,过岚,等.阿替普酶联合长春西汀对急性缺血性脑卒中患者的有效性及安全性研究[J].海南医学,2021,32(5):559-562.[17]李维民,刘晓霞,李娟.豨蛭络达胶囊联合长春西汀治疗急性期风痰瘀血痹阻脉络型脑梗死的疗效观察及其对血液流变学指标的影响[J].中国药物应用与监测,2022,19(4):213-216.[18]朱俊清,俞镜清.长春西汀结合尤瑞克林对急性脑梗死患者炎症反应、神经功能及免疫功能的影响[J].广东医学,2021,42(7):849-853.[19]朱子煜,王祖华,孙文迪,等.醒脑静注射液联合长春西汀注射液治疗对老年急性脑梗死患者认知功能障碍及CysC、hs-CRP水平的影响[J].中国老年学杂志,2021,41(10):2035-2038.[20]秦云,邓国孙.奥扎格雷钠和长春西汀联合高压氧治疗急性脑梗死患者的临床疗效及其作用机制[J].中华航海医学与高气压医学杂志,2020,27(4):444-448,462.

相似文献/References:

[1]刘 阳,李新萍,吴细建.依达拉奉联合脑苷肌肽治疗重症颅脑损伤患者的疗效[J].医学信息,2019,32(22):103.[doi:10.3969/j.issn.1006-1959.2019.22.032]
　LIU Yang,LI Xin-ping,WU Xi-jian.Edaravone Combined with Cerebroside Carnosine in the Treatment of Patients with Severe Head Injury[J].Journal of Medical Information,2019,32(05):103.[doi:10.3969/j.issn.1006-1959.2019.22.032]
[2]李 丹.奥拉西坦和吡拉西坦治疗老年脑出血后认知功能障碍的疗效比较[J].医学信息,2019,32(24):117.[doi:10.3969/j.issn.1006-1959.2019.24.041]
　LI Dan.Efficacy Comparison of the Oxiracetam and Piracetam in the Treatment of Cognitive Impairment in Elderly Patients with Cerebral Hemorrhage[J].Journal of Medical Information,2019,32(05):117.[doi:10.3969/j.issn.1006-1959.2019.24.041]
[3]曹金强,毛士明,汪万国.奥扎格雷联合依达拉奉治疗急性脑梗死的效果[J].医学信息,2020,33(01):140.[doi:10.3969/j.issn.1006-1959.2020.01.044]
　CAO Jin-qiang,MAO Shi-ming,WANG Wan-guo.Effect of Ozagrel Combined with Edaravone on Acute Cerebral Infarction[J].Journal of Medical Information,2020,33(05):140.[doi:10.3969/j.issn.1006-1959.2020.01.044]
[4]谢海辉,张 曙,黎建文,等.依达拉奉对老年髋关节置换术患者血清CXCL13水平及PND的影响[J].医学信息,2020,33(05):67.[doi:10.3969/j.issn.1006-1959.2020.05.020]
　XIE Hai-hui,ZHANG Shu,LI Jian-wen,et al.Effect of Edaravone on Serum CXCL13 Level and PND in Elderly Patients with Hip Replacement[J].Journal of Medical Information,2020,33(05):67.[doi:10.3969/j.issn.1006-1959.2020.05.020]
[5]黄绮娟,陈劲新,黄小良.丁苯酞联合依达拉奉治疗非致残性脑梗死的效果及对患者神经功能的影响[J].医学信息,2021,34(08):144.[doi:10.3969/j.issn.1006-1959.2021.08.038]
　HUANG Qi-juan,CHEN Jin-xin,HUANG Xiao-liang.The Effect of Butylphthalide Combined with Edaravone in the Treatment of Non-disabling Cerebral Infarction and Its Influence on Patients’ Neurological Function[J].Journal of Medical Information,2021,34(05):144.[doi:10.3969/j.issn.1006-1959.2021.08.038]
[6]管海兵,葛 胜,沈 斌.阿托伐他汀钙联合依达拉奉对急性脑梗死患者hs-CRP和同型半胱氨酸水平的影响[J].医学信息,2021,34(19):110.[doi:10.3969/j.issn.1006-1959.2021.19.028]
　GUAN Hai-bing,GE Sheng,SHEN Bin.The Effect of Atorvastatin Calcium Combined with Edaravone on hs-CRP andHomocysteine Levels in Patients with Acute Cerebral Infarction[J].Journal of Medical Information,2021,34(05):110.[doi:10.3969/j.issn.1006-1959.2021.19.028]
[7]荣丽红,张恒春.血栓通联合依达拉奉治疗急性脑梗塞患者的效果[J].医学信息,2021,34(22):148.[doi:10.3969/j.issn.1006-1959.2021.22.046]
　RONG Li-hong,ZHANG Heng-chun.Effect of Xueshuantong Combined with Edaravone on Patients with Acute Cerebral Infarction[J].Journal of Medical Information,2021,34(05):148.[doi:10.3969/j.issn.1006-1959.2021.22.046]
[8]王晓燕.丁苯酞联合依达拉奉、纤溶酶治疗急性脑梗死的疗效及对血清D-二聚体水平的影响[J].医学信息,2025,38(15):67.[doi:10.3969/j.issn.1006-1959.2025.15.013]
　WANG Xiaoyan.Efficacy of Butylphthalide Combined with Edaravone and Fibrinogenase in the Treatmentof Acute Cerebral Infarction and its Effect on Serum D-dimer Level[J].Journal of Medical Information,2025,38(05):67.[doi:10.3969/j.issn.1006-1959.2025.15.013]

更新日期/Last Update: 1900-01-01